Composition for preventing scar adhesion, postoperative anti-adhesion material and application

A composition and anti-adhesion technology, applied in the field of biomedicine, can solve the problems of unsatisfactory anti-adhesion effect, poor pressure resistance, and short drug retention time.

Pending Publication Date: 2021-11-02
SAIKE SAISI BIOTECH CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among the above-mentioned anti-adhesion materials, the anti-adhesion film has moderate flexibility and tissue compatibility. The disadvantage is that the film material has been prefabricated, and the thickness cannot be changed. In some complicated wound sites, the fit with the tissue is low, and leading to a decrease in the effect of anti-adhesion
However, the anti-adhesion solution of chitosan has a short degradation time, and its anti-adhesion effect is not ideal in wounds where chronic inflammation exists, and its anti-compression ability is poor, and the receptor site is greatly affected, so it is not suitable for nerves and other wounds. Adhesion prevention and treatment of surrounding tissues, tendons, etc.
In the way of drug prevention, drugs such as mitomycin C are usually administered directly to the surgical site. In this way, the drug stays in the wound for a short time, and it is difficult to obtain the desired therapeutic effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for preventing scar adhesion, postoperative anti-adhesion material and application
  • Composition for preventing scar adhesion, postoperative anti-adhesion material and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] In this embodiment, a mitomycin C-IFNγ-sodium hyaluronate conjugate is provided, wherein the molecular weight of sodium hyaluronate is 5kDa, and the mitomycin C-IFNγ-sodium hyaluronate conjugate The preparation method is as follows:

[0045] Sodium hyaluronate was dissolved in PBS buffer solution with pH 6.5, after adding an appropriate amount of EDC, stirred at a low speed for 30 minutes at room temperature to activate the carboxyl group of sodium hyaluronate. Dissolve mitomycin C and IFNγ in PBS buffer, slowly add into the activated sodium hyaluronate under stirring condition, after the dropwise addition is completed, stir at room temperature for 8 hours, and dialyze the above-mentioned combination to PBS The product was purified and the purified product was lyophilized for use.

Embodiment 2

[0047] In this embodiment, a mitomycin C-IFNγ-sodium hyaluronate conjugate is provided, wherein the molecular weight of sodium hyaluronate is 10kDa, and the mitomycin C-IFNγ-sodium hyaluronate conjugate The preparation method is as follows:

[0048] Sodium hyaluronate was dissolved in PBS buffer solution with pH 6.0, after adding an appropriate amount of EDC, stirred at a low speed for 35 minutes at room temperature to activate the carboxyl group of sodium hyaluronate. Mitomycin C and IFNγ were dissolved in PBS buffer, slowly added to the activated sodium hyaluronate under stirring conditions, after the addition was completed, stirred at room temperature for 10 hours, and the silk was obtained by column chromatography elution. Split mycin C-IFNγ-sodium hyaluronate conjugate, the purified product is lyophilized for use.

Embodiment 3

[0050] In this embodiment, a mitomycin C-IFNγ-sodium hyaluronate conjugate is provided, wherein the molecular weight of sodium hyaluronate is 10kDa, and the mitomycin C-IFNγ-sodium hyaluronate conjugate The preparation method is as follows:

[0051] Dissolve sodium hyaluronate in PBS buffer at pH 6.0, add appropriate amount of EDC and stir at low speed for 25in at room temperature to activate the carboxyl group of sodium hyaluronate. Mitomycin C and IFNγ were dissolved in PBS buffer, slowly added to the activated sodium hyaluronate under stirring conditions, after the addition was completed, stirred at room temperature for 10 hours, and the silk was obtained by column chromatography elution. Split mycin C-IFNγ-sodium hyaluronate conjugate, the purified product is lyophilized for use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a composition for preventing scar adhesion, a postoperative anti-adhesion material and application. Epidural scar adhesion is an important cause of postoperative lumbar surgery failure syndrome, and the invention aims to provide a drug-loaded postoperative sealing material which can seal wounds and realize stable release of drugs at the same time. The invention firstly provides the mitomycin C-IFN gamma-sodium hyaluronate conjugate for preventing scar adhesion, the conjugate can effectively inhibit scar tissue formation and slow down the drug degradation speed, and when the conjugate is applied to a polyethylene glycol sealant, the sealing effects of low swelling and rapid condensation can be achieved. The product is especially suitable for spinal surgeries such as laminectomy and the like, and has good clinical application value.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a composition for preventing scar adhesion, postoperative anti-adhesion material containing the composition and its application in spinal surgery. Background technique [0002] The information disclosed in this background section is only intended to increase the understanding of the general background of the present invention, and is not necessarily taken as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to those skilled in the art. [0003] Injuries to muscles or ligaments require scar tissue formation to repair. After laminectomy or fenestration, the dura mater is in contact with the muscle and the residual lamina. During the trauma repair process, dense scar tissue will be formed in the lamina defect area, which is called the laminectomy membrane. Adhesion of scar tissue to the dura mater or nerve root ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61K31/728A61K31/407A61K9/06A61K47/18A61K47/34A61P17/02A61P41/00
CPCA61K38/215A61K38/217A61K31/728A61K31/407A61K9/06A61K47/18A61K47/34A61P17/02A61P41/00A61K2300/00
Inventor 苑康见柏桓赵艳张春霞张在庆闫永丽
Owner SAIKE SAISI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap